Will This Orphan Drugmaker Get a Parent Company?
This episode of The Motley Fool's Market Checkup drills down on the days hottest headlines, including more biotech buyout rumors and a hot new biotech start-up.
In this video, health-care analysts David Williamson and Max Macaluso discuss the new rumors that Roche is lining up $15 billion in funding to acquire orphan-disease drugmaker BioMarin. Roche is a would-be serial acquirer, often mentioned as an interested party, but consummating few deals. It balked rather than raise the price of its offer for gene sequencer Illumina. More recently it appeared Roche was interested in Alexion, maker of the blockbuster orphan drug Soliris, as well as pipeline candidate asfotase alfa.
Watch Market Checkup and find out what to make of Roche's denials, its interest in orphan drugs, and why BioMarin would be an intriguing fit for the big pharma.
It's no secret that biotech stocks have been soaring recently, but the best investment strategy is to pick great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" not only shares stocks that could help you build long-term wealth, but also winning strategies that every investor should know. Click here to grab your free copy today.
The article Will This Orphan Drugmaker Get a Parent Company? originally appeared on Fool.com.David Williamson has no position in any stocks mentioned. Follow David on Twitter: @MotleyDavid. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends BioMarin Pharmaceutical and Illumina. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.